Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LY3650150

Phase 3Small molecule

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Perennial Allergic RhinitisActive, not recruiting

Perennial Allergic RhinitisPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)

NCT06338995

Q4 2028

Phase 3Active, not recruiting

Perennial Allergic Rhinitis

NCT06339008

Clinical

Trials by Indication[1]

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06338995·510 enrolled

Perennial Allergic Rhinitis1 trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06339008·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LY3650150. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY3650150 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY3650150. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Related News